All-cause and cardiovascular mortality in treated patients with severe hypertriglyceridaemia: A long-term prospective registry study

Atherosclerosis

Volumn 211, Issue 2, 2010, Pages 618-623

  Neil, H A W ^a   Cooper, J ^b   Betteridge, D J ^b   Capps, N ^c   McDowell, I F W ^d   Durrington, P N ^e   Seed, M ^f   Mann, J I ^g   Humphries, S E ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c PRINCESS ROYAL HOSPITAL   (United Kingdom)

^d UNIVERSITY HOSPITAL OF WALES   (United Kingdom)

^e UNIVERSITY OF MANCHESTER   (United Kingdom)

^f CHARING CROSS HOSPITAL   (United Kingdom)

^g UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

Cardiovascular disease; Coronary heart disease; Hypertriglyceridaemia; Mortality; Triglycerides

Indexed keywords

CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; STANDARDIZED MORTALITY RATIO; STROKE; TRIACYLGLYCEROL BLOOD LEVEL; UNITED KINGDOM;

ADULT; CARDIOVASCULAR DISEASES; COHORT STUDIES; CORONARY DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; HYPERTRIGLYCERIDEMIA; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROSPECTIVE STUDIES; REGISTRIES; RISK; TRIGLYCERIDES;

EID: 77955271958     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.03.006     Document Type: Article

References (23)

1. Griffin B.A., Minihane A.M., Furlonger N., et al. Inter-relationships between small, dense low-density lipoprotein (LDL), plasma triacylglycerol and LDL apoprotein B in an atherogenic lipoprotein phenotype in free-living subjects. Clin Sci 1999, 97:262-276.
2. Sarwar M., Danesh J., Eiriksdottier G., et al. Triglycerides and the risk of coronary heart disease 10158 incident cases among 262525 participants in 29 western prospective studies. Circulation 2007, 115:450-458.
3. Neil H.A.W., Mant D., Jones L., Morgan B., Mann J.I. Lipid screening: is it enough to measure total cholesterol?. BMJ 1990, 301:584-587.
4. Ford E.S., Li C., Zhao G., Pearson W.S., Mokdad A.H. Hypertriglyceridaemia and its pharmacologic treatment among US adults. Arch Intern Med 2009, 169:572-578.
5. Durrington P.N. Hyperlipidaemia. Diagnosis and management 2007, Hodder Arnold, London. 3rd edition.
6. Morganroth J., Levy R.I., Fredrickson D.S. The biochemical, clinical and genetic features of type III hyperlipoproteinaemia. Ann Intern Med 1975, 82:158-174.
7. Shaikh M., Wootton R., Nordestgaard B.F., et al. Quantitative studies of transfer in vivo of low density, sf12-60, and sf60-400 lipoproteins between plasma and arterial intima in humans. Arterioscler Thomb 1991, 11:569-577.
8. Benlian P., De Gennes J.L., Foubert L., et al. Premature atherosclerosis in patients with familial chylomicronemia caused by mutations in the lipoprotein lipase gene. NEJM 1996, 335:848-854.
9. Neil H.A.W., Cooper J., Betteridge D.J., et al. Reductions in all-cause, cancer and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J 2008, 29:2625-2633.
10. Coleman M., Douglas A., Herman C., Peto J. Cohort study analysis with a Fortran computer program. Int J Epidemiol 1999, 15:134-137.
11. Hokanson J.E., Austin M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996, 3:213-219.
12. Nordestgaard B.G., Benn M., Schnor P., Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007, 298:299-308.
13. Health Survey for England. Vol. 2. Risk factors for cardiovascular disease. Series HS No 13.
14. Asia Pacific Cohort Studies Collaboration Serum triglycerides as a risk factor for cardiovascular risk in the Asia-Pacific region. Circulation 2004, 110:2678-2686.
15. The Emerging Risk Factors Collaboration Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009, 302:1993-2000.
16. Wang J., Cao H., Ban M.R., et al. Resequencing genomic DNA of patients with severe hypertriglyceridemia (MIM 144650). Arterioscler Thromb Vasc Biol 2007, 27:2450-2455.
17. Wang J., Ban M.R., Zou G.Y., et al. Polygenic determinants of severe hypertriglyceridemia. Hum Mol Genet 2008, 17:2894-2899.
18. Wang J., Ban M.R., Kennedy B.A., et al. APOA5 genetic variants are markers for classic hyperlipoproteinemia phenotypes and hypertriglyceridemia. Nat Clin Pract Cardiovasc Med 2008, 5:730-737.
19. Linsel-Nitschke P., Götz A., Erdmann J., et al. Lifelong reduction of LDL-cholesterol related to a common variant in the LDL-receptor gene decreases the risk of coronary artery disease-a Mendelian Randomisation study. PLoS One 2008, 3(8):e2986.
20. de Beer F., Stalenhoef A.F.H., Hoogerbrugge N., et al. Expression of type III hyperlipoproteinemia in apolipoprotein E2 (Arg158→Cys) homozygotes is associated with hyperinsulinemia. Arterioscler Thromb Vasc Biol 2002, 22:294-299.
21. Brunzell J.D., Albers J.J., Chait A., et al. Plasma lipoproteins in familial combined and mongenic familial hypertriglyceridemia. J Lipid Res 1983, 24:147-155.
22. Austin M.A., McKnight B., Edwards K.L., et al. Cardiovascular mortality in familial forms of hypertriglyceridaemia: a 20-year prospective study. Circulation 2000, 101:2777-2782.
23. Durrington P.N., Bolton C.H., Hartog M. Serum and lipoprotein B levels in normal subjects and patients with hyperlipoproteinaemia. Clin Chim Acta 1978, 82:151-160.